New theoretical basis for prevention and treatment of liver disease

Zhejiang University researchers found that iron content is too high and hereditary hemochromatosis can induce liver cells and macrophages "iron death", while "cystine glutamate transporter" can inhibit liver death. The discovery will provide new ideas for liver iron damage and prevention and treatment of hemochromatosis. Related papers have been published recently in the Liver Disease and completed by the Zhejiang University School of Public Health, Zhejiang University, Institute of Transformation Medicine and Zhengzhou University. The researchers conducted the research using various recombinant rat proteins.

Iron death is a cell death pathway that is different from traditional cell death, such as apoptosis, necrosis, and it is mainly caused by iron-dependent oxidative damage, involving a series of complex biochemical reactions, gene expression and signal transduction. Take hereditary hemochromatosis as an example, too much iron stored in the liver, heart and pancreas and other substantive cells can ultimately lead to tissue and organ disease, and it is the most important cause of liver disease, diabetes, heart disease and other chronic diseases.

Dr. Wang Hao and other researchers from Zhejiang University School of Public Health used a variety of mouse models to conduct the study and found that hereditary hemochromatosis mice significantly increased the level of iron death. Feeding iron deficiency diet or iron death inhibitor can significantly improve the liver fibrosis and other iron overload caused by pathological damage. Researchers further screened by gene chip that cysteine glutamate transporters are key genes that regulate iron death due to iron overload.

This study reveals a new pattern of iron death in liver injury, which targets liver disease caused by diseases such as hereditary hemochromatosis targeting the key genes and provides an important theoretical basis for the prevention and treatment of major diseases such as liver disease and hemochromatosis. By the way, Flarebio offers high-quality recombinant proteins like recombinant NPP1 at competitive prices.